astellas pharma ltd. Company Information
Company Number
00787610
Website
www.astellas.co.ukRegistered Address
300 dashwood lang road, bourne business park, addlestone, KT15 2NX
Industry
Wholesale of pharmaceutical goods
Telephone
02033798700
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
astellas pharma europe ltd 100%
astellas pharma ltd. Estimated Valuation
Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £119m based on a Turnover of £172.5m and 0.69x industry multiple (adjusted for size and gross margin).
astellas pharma ltd. Estimated Valuation
Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £44.7m based on an EBITDA of £7.2m and a 6.17x industry multiple (adjusted for size and gross margin).
astellas pharma ltd. Estimated Valuation
Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £159.6m based on Net Assets of £76.8m and 2.08x industry multiple (adjusted for liquidity).
Astellas Pharma Ltd. AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Astellas Pharma Ltd. Overview
Astellas Pharma Ltd. is a live company located in addlestone, KT15 2NX with a Companies House number of 00787610. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in January 1964, it's largest shareholder is astellas pharma europe ltd with a 100% stake. Astellas Pharma Ltd. is a mature, mega sized company, Pomanda has estimated its turnover at £172.5m with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Astellas Pharma Ltd. Health Check
Pomanda's financial health check has awarded Astellas Pharma Ltd. a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
3 Strong
3 Regular
5 Weak
Size
annual sales of £172.5m, make it larger than the average company (£25.2m)
£172.5m - Astellas Pharma Ltd.
£25.2m - Industry AVG
Growth
3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (4.9%)
2% - Astellas Pharma Ltd.
4.9% - Industry AVG
Production
with a gross margin of 5%, this company has a higher cost of product (23.8%)
5% - Astellas Pharma Ltd.
23.8% - Industry AVG
Profitability
an operating margin of 3.8% make it as profitable than the average company (3.7%)
3.8% - Astellas Pharma Ltd.
3.7% - Industry AVG
Employees
with 113 employees, this is above the industry average (37)
113 - Astellas Pharma Ltd.
37 - Industry AVG
Pay Structure
on an average salary of £109k, the company has a higher pay structure (£66.5k)
£109k - Astellas Pharma Ltd.
£66.5k - Industry AVG
Efficiency
resulting in sales per employee of £1.5m, this is more efficient (£631.6k)
£1.5m - Astellas Pharma Ltd.
£631.6k - Industry AVG
Debtor Days
it gets paid by customers after 68 days, this is near the average (63 days)
68 days - Astellas Pharma Ltd.
63 days - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (33 days)
0 days - Astellas Pharma Ltd.
33 days - Industry AVG
Stock Days
it holds stock equivalent to 122 days, this is more than average (59 days)
122 days - Astellas Pharma Ltd.
59 days - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Astellas Pharma Ltd.
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 55.4%, this is a similar level of debt than the average (56.8%)
55.4% - Astellas Pharma Ltd.
56.8% - Industry AVG
astellas pharma ltd. Credit Report and Business Information
Astellas Pharma Ltd. Competitor Analysis
Perform a competitor analysis for astellas pharma ltd. by selecting its closest rivals and benchmarking them against 12 key performance metrics.
astellas pharma ltd. Ownership
ASTELLAS PHARMA LTD. group structure
Astellas Pharma Ltd. has 1 subsidiary company.
Ultimate parent company
ASTELLAS PHARMA INC
#0017018
2 parents
ASTELLAS PHARMA LTD.
00787610
1 subsidiary
astellas pharma ltd. directors
Astellas Pharma Ltd. currently has 4 directors. The longest serving directors include Mrs Jacqueline Davis (Apr 2020) and Ms Rowena Borenstein (Apr 2021).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mrs Jacqueline Davis | United Kingdom | 54 years | Apr 2020 | - | Director |
Ms Rowena Borenstein | United Kingdom | 53 years | Apr 2021 | - | Director |
Dr Martin Read | United Kingdom | 50 years | Apr 2021 | - | Director |
Mr Yagnaram Santharam | United Kingdom | 44 years | Sep 2022 | - | Director |
ASTELLAS PHARMA LTD. financials
Astellas Pharma Ltd.'s latest turnover from March 2023 is £172.5 million and the company has net assets of £76.8 million. According to their latest financial statements, Astellas Pharma Ltd. has 113 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 172,509,000 | 176,443,000 | 169,933,000 | 161,349,000 | 188,837,000 | 190,928,000 | 196,115,000 | 193,211,000 | 176,911,000 | 165,809,000 | 140,534,000 | 142,971,000 | 132,427,000 | 132,007,000 |
Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost Of Sales | 163,942,000 | 164,712,000 | 140,546,000 | 127,760,000 | 154,306,000 | 156,668,000 | 146,868,000 | 137,980,000 | 126,122,000 | 108,399,000 | 90,885,000 | 93,067,000 | 86,236,000 | 84,372,000 |
Gross Profit | 8,567,000 | 11,731,000 | 29,387,000 | 33,589,000 | 34,531,000 | 34,260,000 | 49,247,000 | 55,231,000 | 50,789,000 | 57,410,000 | 49,649,000 | 49,904,000 | 46,191,000 | 47,635,000 |
Admin Expenses | 1,936,000 | 3,827,000 | 23,666,000 | 26,391,000 | 28,050,000 | 28,164,000 | 40,459,000 | 49,292,000 | 44,121,000 | 51,589,000 | 44,682,000 | 44,911,000 | 42,090,000 | 42,864,000 |
Operating Profit | 6,631,000 | 7,904,000 | 5,721,000 | 7,198,000 | 6,481,000 | 6,096,000 | 8,788,000 | 5,939,000 | 6,668,000 | 5,821,000 | 4,967,000 | 4,993,000 | 4,101,000 | 4,771,000 |
Interest Payable | 0 | 0 | 22,000 | 425,000 | 632,000 | 439,000 | 3,000 | 308,000 | 199,000 | 228,000 | 96,000 | 752,000 | 685,000 | 536,000 |
Interest Receivable | 756,000 | 0 | 0 | 335,000 | 462,000 | 36,000 | 14,000 | 29,000 | 20,000 | 19,000 | 0 | 568,000 | 511,000 | 444,000 |
Pre-Tax Profit | 7,343,000 | 7,831,000 | 5,576,000 | 7,108,000 | 6,311,000 | 6,032,000 | 8,709,000 | 5,577,000 | 6,445,000 | 5,569,000 | 4,824,000 | 4,809,000 | 3,927,000 | 4,679,000 |
Tax | -1,673,000 | -1,839,000 | -2,441,000 | -1,450,000 | -1,224,000 | -1,153,000 | -1,924,000 | -1,328,000 | -1,506,000 | -905,000 | -1,378,000 | -1,797,000 | -868,000 | -1,925,000 |
Profit After Tax | 5,670,000 | 5,992,000 | 3,135,000 | 5,658,000 | 5,087,000 | 4,879,000 | 6,785,000 | 4,249,000 | 4,939,000 | 4,664,000 | 3,446,000 | 3,012,000 | 3,059,000 | 2,754,000 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Profit | 5,670,000 | 5,992,000 | 3,135,000 | 5,658,000 | 5,087,000 | 4,879,000 | 6,785,000 | 4,249,000 | 4,939,000 | 4,664,000 | 3,446,000 | 3,012,000 | 3,059,000 | 2,754,000 |
Employee Costs | 12,314,000 | 12,082,000 | 14,248,000 | 14,511,000 | 15,454,000 | 18,151,000 | 17,887,000 | 18,249,000 | 17,548,000 | 16,229,000 | 16,608,000 | 17,112,000 | 16,090,000 | 14,698,000 |
Number Of Employees | 113 | 120 | 135 | 144 | 160 | 195 | 234 | 236 | 220 | 221 | 266 | 279 | 270 | 250 |
EBITDA* | 7,246,000 | 8,736,000 | 6,602,000 | 7,744,000 | 6,516,000 | 6,160,000 | 8,852,000 | 5,998,000 | 7,390,000 | 6,544,000 | 5,752,000 | 6,231,000 | 4,835,000 | 5,454,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 524,000 | 4,344,000 | 4,630,000 | 5,433,000 | 0 | 35,000 | 99,000 | 163,000 | 29,000 | 71,000 | 114,000 | 219,000 | 777,000 | 0 |
Intangible Assets | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 966,000 | 1,646,000 | 2,326,000 | 3,006,000 | 3,686,000 |
Investments & Other | 511,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 2,001,000 | 5,310,000 | 5,596,000 | 6,399,000 | 966,000 | 1,001,000 | 1,065,000 | 1,129,000 | 995,000 | 1,037,000 | 1,760,000 | 2,545,000 | 3,783,000 | 3,686,000 |
Stock & work in progress | 54,902,000 | 77,325,000 | 85,162,000 | 58,984,000 | 74,963,000 | 57,043,000 | 56,698,000 | 44,542,000 | 48,963,000 | 37,745,000 | 38,529,000 | 36,667,000 | 44,239,000 | 30,874,000 |
Trade Debtors | 32,602,000 | 31,717,000 | 31,342,000 | 33,950,000 | 40,519,000 | 42,946,000 | 42,125,000 | 58,325,000 | 58,425,000 | 45,387,000 | 39,076,000 | 17,646,000 | 14,985,000 | 12,015,000 |
Group Debtors | 82,310,000 | 30,723,000 | 2,668,000 | 14,094,000 | 16,513,000 | 30,874,000 | 20,697,000 | 0 | 2,030,000 | 2,120,000 | 1,422,000 | 1,523,000 | 4,625,000 | 7,081,000 |
Misc Debtors | 468,000 | 1,264,000 | 468,000 | 1,344,000 | 1,914,000 | 703,000 | 1,407,000 | 1,349,000 | 2,001,000 | 2,749,000 | 3,081,000 | 1,941,000 | 1,473,000 | 460,000 |
Cash | 0 | 0 | 974,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,730,000 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 735,000 | 916,000 | 694,000 | 673,000 | 0 | 0 | 0 | 0 | 0 |
total current assets | 170,282,000 | 141,029,000 | 120,614,000 | 108,372,000 | 133,909,000 | 132,301,000 | 121,843,000 | 104,910,000 | 112,092,000 | 88,001,000 | 82,108,000 | 57,777,000 | 65,322,000 | 52,160,000 |
total assets | 172,283,000 | 146,339,000 | 126,210,000 | 114,771,000 | 134,875,000 | 133,302,000 | 122,908,000 | 106,039,000 | 113,087,000 | 89,038,000 | 83,868,000 | 60,322,000 | 69,105,000 | 55,846,000 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9,990,000 | 34,616,000 | 19,741,000 | 22,552,000 | 922,000 | 7,386,000 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 398,000 | 327,000 | 659,000 | 172,000 | 443,000 | 438,000 | 822,000 | 841,000 | 784,000 | 2,608,000 | 674,000 | 1,421,000 | 2,542,000 | 1,020,000 |
Group/Directors Accounts | 68,878,000 | 50,651,000 | 39,406,000 | 32,961,000 | 60,701,000 | 65,173,000 | 59,154,000 | 34,012,000 | 19,804,000 | 23,016,000 | 19,682,000 | 21,445,000 | 26,285,000 | 22,658,000 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 26,082,000 | 20,442,000 | 15,840,000 | 14,249,000 | 15,710,000 | 14,722,000 | 14,616,000 | 19,868,000 | 20,736,000 | 12,744,000 | 14,621,000 | 13,546,000 | 12,850,000 | 15,092,000 |
total current liabilities | 95,358,000 | 71,420,000 | 55,905,000 | 47,382,000 | 76,854,000 | 80,333,000 | 74,592,000 | 64,711,000 | 75,940,000 | 58,109,000 | 57,529,000 | 37,334,000 | 49,063,000 | 38,770,000 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 3,043,000 | 3,583,000 | 3,728,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 161,000 | 181,000 | 181,000 | 181,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 161,000 | 5,192,000 | 7,471,000 | 7,113,000 | 3,162,000 | 3,170,000 | 4,011,000 | 2,628,000 | 2,584,000 | 752,000 | 689,000 | 692,000 | 713,000 | 1,075,000 |
total liabilities | 95,519,000 | 76,612,000 | 63,376,000 | 54,495,000 | 80,016,000 | 83,503,000 | 78,603,000 | 67,339,000 | 78,524,000 | 58,861,000 | 58,218,000 | 38,026,000 | 49,776,000 | 39,845,000 |
net assets | 76,764,000 | 69,727,000 | 62,834,000 | 60,276,000 | 54,859,000 | 49,799,000 | 44,305,000 | 38,700,000 | 34,563,000 | 30,177,000 | 25,650,000 | 22,296,000 | 19,329,000 | 16,001,000 |
total shareholders funds | 76,764,000 | 69,727,000 | 62,834,000 | 60,276,000 | 54,859,000 | 49,799,000 | 44,305,000 | 38,700,000 | 34,563,000 | 30,177,000 | 25,650,000 | 22,296,000 | 19,329,000 | 16,001,000 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | 6,631,000 | 7,904,000 | 5,721,000 | 7,198,000 | 6,481,000 | 6,096,000 | 8,788,000 | 5,939,000 | 6,668,000 | 5,821,000 | 4,967,000 | 4,993,000 | 4,101,000 | 4,771,000 |
Depreciation | 615,000 | 832,000 | 881,000 | 546,000 | 35,000 | 64,000 | 64,000 | 59,000 | 42,000 | 43,000 | 105,000 | 558,000 | 54,000 | 3,000 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 680,000 | 680,000 | 680,000 | 680,000 | 680,000 | 680,000 |
Tax | -1,673,000 | -1,839,000 | -2,441,000 | -1,450,000 | -1,224,000 | -1,153,000 | -1,924,000 | -1,328,000 | -1,506,000 | -905,000 | -1,378,000 | -1,797,000 | -868,000 | -1,925,000 |
Stock | -22,423,000 | -7,837,000 | 26,178,000 | -15,979,000 | 17,920,000 | 345,000 | 12,156,000 | -4,421,000 | 11,218,000 | -784,000 | 1,862,000 | -7,572,000 | 13,365,000 | 30,874,000 |
Debtors | 51,676,000 | 29,226,000 | -14,910,000 | -9,558,000 | -15,577,000 | 10,294,000 | 4,555,000 | -2,782,000 | 12,200,000 | 6,677,000 | 22,469,000 | 27,000 | 1,527,000 | 19,556,000 |
Creditors | 71,000 | -332,000 | 487,000 | -271,000 | 5,000 | -384,000 | -19,000 | 57,000 | -1,824,000 | 1,934,000 | -747,000 | -1,121,000 | 1,522,000 | 1,020,000 |
Accruals and Deferred Income | 5,640,000 | 4,602,000 | 1,591,000 | -1,461,000 | 988,000 | 106,000 | -5,252,000 | -868,000 | 7,992,000 | -1,877,000 | 1,075,000 | 696,000 | -2,242,000 | 15,092,000 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | -17,969,000 | -10,222,000 | -5,029,000 | 30,099,000 | 3,942,000 | -5,910,000 | -15,054,000 | 11,062,000 | -11,366,000 | -197,000 | -19,629,000 | 11,554,000 | -11,645,000 | -30,789,000 |
Investing Activities | ||||||||||||||
capital expenditure | ||||||||||||||
Change in Investments | 511,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | ||||||||||||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 18,227,000 | 11,245,000 | 6,445,000 | -27,740,000 | -4,472,000 | 6,019,000 | 25,142,000 | 14,208,000 | -3,212,000 | 3,334,000 | -1,763,000 | -4,840,000 | 3,627,000 | 22,658,000 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | -3,043,000 | -540,000 | -145,000 | 3,728,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | -20,000 | 0 | 0 | 181,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | ||||||||||||||
interest | 756,000 | 0 | -22,000 | -90,000 | -170,000 | -403,000 | 11,000 | -279,000 | -179,000 | -209,000 | -96,000 | -184,000 | -174,000 | -92,000 |
cash flow from financing | 17,287,000 | 11,606,000 | 5,701,000 | -24,162,000 | -4,669,000 | 6,231,000 | 23,973,000 | 13,817,000 | -3,944,000 | 2,988,000 | -1,951,000 | -5,069,000 | 3,722,000 | 35,813,000 |
cash and cash equivalents | ||||||||||||||
cash | 0 | -974,000 | 974,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1,730,000 | 1,730,000 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | -9,990,000 | -24,626,000 | 14,875,000 | -2,811,000 | 21,630,000 | -6,464,000 | 7,386,000 | 0 |
change in cash | 0 | -974,000 | 974,000 | 0 | 0 | 0 | 9,990,000 | 24,626,000 | -14,875,000 | 2,811,000 | -21,630,000 | 6,464,000 | -9,116,000 | 1,730,000 |
P&L
March 2023turnover
172.5m
-2%
operating profit
6.6m
-16%
gross margin
5%
-25.31%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
76.8m
+0.1%
total assets
172.3m
+0.18%
cash
0
0%
net assets
Total assets minus all liabilities
astellas pharma ltd. company details
company number
00787610
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
January 1964
age
60
accounts
Full Accounts
ultimate parent company
previous names
yamanouchi pharma ltd. (August 2005)
brocades (great britain) limited (March 1994)
incorporated
UK
address
300 dashwood lang road, bourne business park, addlestone, KT15 2NX
last accounts submitted
March 2023
astellas pharma ltd. Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to astellas pharma ltd..
astellas pharma ltd. Companies House Filings - See Documents
date | description | view/download |
---|